Market Size (2015)
2015
$2.00B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2015)
2015
$2.00B
Projected (2023)
2023
$3.15B
CAGR (2015–2023)
5.8%
5.8%Key Players
109+
The growth of the Cardiopulmonary Exercise Testing Market is attributed to the increase in the prevalence of cardiovascular diseases and the rising geriatric population, and the growing adoption in emerging economies. However, the lack of skilled and experienced professionals is anticipated to hamper market growth.
The Cardiopulmonary Exercise Testing Market market is projected to grow at a CAGR of 5.8% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCardiopulmonary Exercise Testing (CPET) is an exercise test that assesses submaximal and maximum exercise response involving the pulmonary, circulatory, hematopoietic, cognitive, and skeletal muscle systems in order to analyze diagnostic and prognostic assessment. Additionally, CPET is being utilized more frequently in a broad range of therapeutic applications for the objective diagnosis of functional capacity and impairment as well as for the evaluation of undiagnosed exercise intolerance.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2015 – 2018
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2018) and forecast period (2018–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat Of New Entrants
The threat of new entrants in the Cardiopulmonary Exercise Testing (CPET) market is moderate. While there are barriers to entry, such as the need for specialized equipment, expertise in exercise physiology, and regulatory compliance, it is relatively easier for new players to enter compared to highly regulated industries like pharmaceuticals. The availability of CPET systems from various manufacturers and the potential for technological advancements in the field create opportunities for new entrants to introduce innovative products. However, established companies with established brand reputation, extensive customer base, and strong distribution networks may have a competitive advantage over new entrants. These established players have invested significant resources in research and development, built relationships with healthcare providers and research institutions, and obtained necessary regulatory approvals. This makes it challenging for new entrants to gain market share and establish themselves as credible competitors.
Bargaining Power Of Suppliers
The bargaining power of suppliers in the Cardiopulmonary Exercise Testing Market is moderate. Suppliers in this context include manufacturers of exercise testing equipment, sensors, and related accessories. While there may be moderate number of suppliers available, their bargaining power can vary based on factors such as the availability of alternative suppliers, the uniqueness or proprietary nature of their products, and the importance of their offerings to CPET systems. In some cases, suppliers with limited competition or with patented technologies may have more leverage in negotiations. However, the presence of standardized equipment and accessories in the market can mitigate supplier power to some extent, as buyers have the option to switch between suppliers. Additionally, manufacturers of CPET systems may work closely with suppliers to develop customized solutions or establish long-term partnerships, which can influence supplier power. Overall, while suppliers in the CPET market can hold some bargaining power, factors such as the availability of alternatives and the ability of buyers to switch suppliers can help to balance the power dynamics in supplier-buyer relationships.
Threat Of Substitutes
The threat of substitutes in the Cardiopulmonary Exercise Testing (CPET) market is relatively low. CPET offers a comprehensive assessment of cardiopulmonary function and is considered the gold standard for evaluating exercise capacity and cardiorespiratory fitness. While there are alternative exercise testing methods available, such as stress echocardiography or stress electrocardiography, they do not provide the same level of comprehensive data and insights as CPET. CPET allows for the simultaneous measurement of various physiological parameters, including oxygen consumption, carbon dioxide production, ventilation, heart rate, and blood pressure response during exercise. Moreover, CPET is particularly valuable in diagnosing and managing cardiopulmonary diseases, as it can assess the functional capacity of the cardiovascular and respiratory systems. The accuracy and reliability of CPET in providing clinically relevant information make it less susceptible to direct substitutes.
Bargaining Power Of Buyers
The bargaining power of buyers in the Cardiopulmonary Exercise Testing Market is generally low. Several factors contribute to the low bargaining power of buyers. Firstly, the CPET market is characterized by a limited number of suppliers, often dominated by established manufacturers. This lack of competition among suppliers reduces buyers' options and weakens their ability to negotiate favorable terms. Additionally, the importance of CPET in diagnosing and managing cardiopulmonary conditions creates a high level of dependence on CPET systems and related services. Buyers require these tools to provide accurate assessments of patients' cardiorespiratory fitness and guide treatment decisions, making CPET a critical component of their operations. Moreover, the specialized nature of CPET equipment and the need for compatibility with existing infrastructure can make it challenging for buyers to easily switch between suppliers. This lack of flexibility strengthens the position of suppliers, who may be less inclined to offer significant price concessions or other favorable terms. Overall, the low bargaining power of buyers in the CPET market highlights the strong position of suppliers and the importance of CPET as an essential tool in the healthcare industry.
Intensity Of Rivalry
The intensity of competitive rivalry in the Cardiopulmonary Exercise Testing (CPET) market is high. The market is populated by several established players, including manufacturers of CPET systems and related accessories. Competition in this industry is driven by factors such as product features, accuracy and reliability of measurements, ease of use, pricing, and customer support. Manufacturers strive to differentiate themselves through technological advancements, offering innovative features and improvements in user experience. They invest in research and development to stay at the forefront of CPET technology, constantly seeking to outperform competitors and gain a competitive edge. Additionally, established players may leverage their brand reputation, customer relationships, and distribution networks to maintain a competitive advantage. They invest in marketing and customer support activities to retain existing customers and attract new ones. The high intensity of competitive rivalry fosters ongoing innovation and product development, benefiting buyers with a wide range of options and advancements in CPET technology. Manufacturers need to continually adapt and differentiate themselves to thrive in this competitive landscape.
Market estimates by geography (2023)
InsightAmericas leads with $1.22B by 2023, while Asia Pacific is projected to grow fastest at a 6.1% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2018 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $622.69M | $786.32M | $984.84M | 5.9% | 31% |
| Asia Pacific | $441.73M | $550.78M | $711.02M | 6.1% | 23% |
| Middle East and Africa | $154.04M | $192.50M | $235.46M | 5.4% | 7% |
| Americas | $786.22M | $986.97M | $1.22B | 5.7% | 39% |
| Total | $2.00B | $2.52B | $3.15B | 5.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$3.15B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cardiopulmonary Exercise Testing (CPET) Systems | $1.42B | 5.8% | 46% |
| Single-Photon Emission Computed Tomography (SPECT) | $740.21M | 5.8% | 53% |
| Echocardiogram | $362.20M | 5.8% | 89% |
| Pulse Oximeters | $279.61M | 5.8% | 72% |
| Stress Blood Pressure Monitors | $186.32M | 5.8% | 89% |
| Others | $160.83M | 5.8% | 53% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Cardiopulmonary Exercise Testing Market covering market dynamics, competitive landscape, and strategic outlook.
The Cardiopulmonary Exercise Testing Market market is projected to reach $3.15B by 2023, growing at 5.8% CAGR. The Cardiopulmonary Exercise Testing (CPET) Systems segment holds the largest share.
The global Cardiopulmonary Exercise Testing Market is emerging due to an increase in the prevalence of cardiovascular diseases and a rising geriatric population. Additionally, a growing number of strategic initiatives will provide growth opportunities for the market in the future. However, a lack of skilled and experienced professionals might hamper the market's growth in the forecast period.
The growing prevalence of cardiovascular diseases such as heart failure, and pulmonary hypertension among others across the globe is driving the growth of the Cardiopulmonary Exercise Testing Market. Cardiopulmonary Exercise Testing provides valuable diagnostic information and helps in determining exercise capacity and functional limitations in patients with these conditions. According to the article published by National Center for Biotechnology Information in June 2022, the test can provide both cardiac and pulmonary disease processes, while aiding in the development of individualized therapy and rehabilitation programs. Moreover, the increasing prevalence of cardiovascular diseases can be attributed to various factors, including aging populations, sedentary lifestyles, smoking, air pollution, and unhealthy diets. As these diseases progress, they lead to functional limitations, reduced exercise tolerance, and impaired cardiopulmonary fitness.
In this context, Cardiopulmonary Exercise Testing (CPET) plays a crucial role in assessing and managing these conditions. It provides comprehensive information on an individual's exercise capacity, oxygen uptake, ventilation, and cardiac response during exercise. Cardiopulmonary Exercise Testing results can guide treatment decisions, exercise prescriptions, and rehabilitation programs tailored to each patient's needs. As it enables healthcare professionals to monitor disease progression, evaluate treatment efficacy, and optimize management strategies for respiratory and cardiovascular diseases. Overall, the growing prevalence of chronic respiratory and cardiovascular diseases underscores the importance of CPET as a diagnostic and therapeutic tool. It enables comprehensive evaluation and personalized management, helping healthcare providers address the challenges posed by these conditions and improve patient outcomes. Thus, the aforementioned factors help to propel the Cardiopulmonary Exercise Testing Market in the forecasting period.
Cardiopulmonary Exercise Testing assists in allowing dynamic and accurate assessment of pulmonary and cardiac performance during exercise. It is mainly utilized to assess the health of the cardiopulmonary organs of a patient. Cardiopulmonary Exercise Testing helps physicians in measuring accurately anticipated outcomes and exercise capacity in patients with heart disease. Rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships to gain a competitive edge and offer advanced treatment options for Cardiopulmonary Exercise Testing. For instance, in November 2021, COSMED SRL (Italy) launched the 2° generation of OMNIA 2.1 Software, to help clinicians, researchers, and health professionals to provide the highest standard of data management. This is the most comprehensive data management platform for metabolic, lung function and body composition assessment, and Cardiopulmonary Exercise Testing. Similarly, in June 2020, MGC Diagnostics (US) signed a distribution agreement with Monitored Therapeutics, Inc. (MTI) (US). This agreement will help MGC Diagnostics to apply its expertise in diagnostic equipment and cardiopulmonary products to offer in-home solutions and to help medical professionals. Hence, above mentioned initiatives will help to boost the market during the forecast period.
The lack of skilled and experienced professionals such as CPET specialists, and CPET technicians among others adversely affects the growth of the global Cardiopulmonary Exercise Testing Market. In addition, Cardiopulmonary Exercise Testing requires skilled personnel for its proper conduct. Moreover, retiring skilled technicians without being replaced by new ones also creates a significant shortage of specialists. Interpreting CPET results requires specialized knowledge and expertise. The scarcity of skilled professionals who can accurately analyze and interpret CPET data poses a challenge to the widespread adoption of CPET. Training programs and education initiatives are necessary to address this limitation. Furthermore, the slow adoption of new technologies in developing countries also hampers the growth of the Global Cardiopulmonary Exercise Testing Market.
The COVID-19 pandemic has had a significant impact on the supply chains in the Cardiopulmonary Exercise Testing (CPET) market. The global outbreak disrupted supply chains worldwide, causing delays, shortages, and logistical challenges across various industries, including healthcare. One major effect of the pandemic was the disruption of manufacturing and production processes. Many CPET system manufacturers faced disruptions in their operations due to factory closures, restrictions on workforce, and supply chain interruptions. The lockdown measures imposed by governments to control the spread of the virus led to labor shortages, transportation restrictions, and a scarcity of raw materials, components, and parts. These disruptions resulted in delays in the production and delivery of CPET systems, affecting the availability of equipment in the market.
However, the pandemic also prompted some positive changes in the CPET supply chains. Manufacturers adapted to the situation by implementing safety protocols, increasing automation, and diversifying their supplier base. Many companies also explored local sourcing options to reduce dependencies on international suppliers and mitigate future risks.
COVID-19 pandemic has had a substantial impact on key players in the Cardiopulmonary Exercise Testing Market. These players include manufacturers of CPET systems, distributors, and healthcare providers utilizing CPET technology. The pandemic has presented both challenges and opportunities for these stakeholders. One of the major challenges faced by CPET system manufacturers was the disruption in their production and supply chains. The global lockdowns and restrictions imposed to curb the spread of the virus resulted in temporary closures of manufacturing facilities, leading to delays in production and delivery timelines. The scarcity of raw materials, components, and parts further exacerbated the situation. As a result, some key players experienced a decline in their manufacturing output and faced challenges in meeting the increased demand for CPET systems during the pandemic. Furthermore, the reduced healthcare facility capacity and focus on COVID-19 management led to a decline in routine medical procedures, including CPET testing. Many healthcare providers had to prioritize their resources and redirect their efforts towards COVID-19 patients, resulting in a temporary decrease in the demand for CPET testing services. This decline in demand had a direct impact on the revenue and profitability of key players in the CPET market.
However, the pandemic also created opportunities for key players to innovate and adapt to the changing circumstances. Some CPET system manufacturers quickly responded by developing remote monitoring capabilities and telehealth solutions, enabling patients to undergo CPET testing remotely, minimizing the need for in-person visits. This adaptation helped to maintain a level of service provision during the pandemic and mitigate the impact on revenue streams. Additionally, key players in the CPET market witnessed a growing awareness of the importance of respiratory health and exercise testing in managing COVID-19 cases. CPET testing has been utilized to evaluate cardiopulmonary function in COVID-19 patients and assess their readiness for hospital discharge. This increased recognition of the value of CPET testing in COVID-19 management presented an opportunity for key players to collaborate with healthcare providers and contribute to the broader efforts to combat the pandemic.
The COVID-19 pandemic has had a significant impact on the demand for Cardiopulmonary Exercise Testing (CPET). According to a study published in the Journal of Cardiopulmonary Rehabilitation and Prevention, in 2020-2021 there was a 59% reduction in CPET utilization during the early months of the pandemic compared to pre-pandemic levels. The prioritization of essential healthcare services and the temporary suspension of non-urgent procedures led to a decline in CPET demand. Additionally, the adoption of telemedicine and remote monitoring solutions during the pandemic further affected the demand for traditional in-person CPET testing. As healthcare systems recover and adapt, the demand for CPET is expected to rebound, considering the continued need for accurate assessment and monitoring of cardiopulmonary function in patients with respiratory and cardiovascular conditions.
Profiles of 109 companies operating in the Cardiopulmonary Exercise Testing Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Masimo Corporation
Company Headquarter: US Founded: 1989 Workforce: ~4000 Company Working: Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, respiration rate from the pleth, noninvasively monitor hemoglobin concentration, carboxyhemoglobin and methemoglobin saturation, monitor arterial oxygen saturation, and acoustic respiration rate and calculates oxygen content and oxygen reserve index.
Schiller AG
Company Headquarters: Baar, Switzerland Founded: 1974 Workforce: ~ 1,200 Company Working: Schiller AG (Schiller) is a manufacturer and supplier of cardiopulmonary diagnostics, defibrillation, and patient monitoring devices as well as a software solution. It offers electrocardiography, emergency care and resuscitation, pulmonary function testing, blood pressure, diagnostic station, radiology and interventional cardiology, patient monitoring, critical care, medical IT, robotics, and consumables. It also offers ECG simulation-based e-training services. Moreover, the company distributes products directly and through a network of distributors across the world. Furthermore, the company has its facilities in France, Switzerland, Germany, India, China, and Austria.
Nihon Kohden Corporation
Company Headquarters: Tokyo, Japan Founded: 1951 Workforce: ~5,169 Company Working: NIHON KOHDEN CORPORATION is a leading manufacturer, developer, and distributor of electronic equipment. It operates through three segments: neuro, newborn care, and hearing and balance. It has continued to supply a wide range of electronic medical equipment, such as EEG, EMG/EP measuring systems, electrocardiographs, defibrillators, and hematology analyzers. Medical Electronics or Medical Engineering (ME) is the union of medicine and engineering. In addition, it provides patient monitor systems that include central monitors, bedside monitors, wireless monitors, remote access software, and other equipment, as well as clinical information systems and related consumables such as electrodes and sensors. The company has sales subsidiaries in the US, Mexico, Colombia, Brazil, Germany, France, Spain, Italy, the UK, China, Singapore, Thailand, Malaysia, India, the UAE, and Korea. A network of distributors covers the countries where it does not have a direct sales system. Its products are exported all over the world.
MGC Diagnostics Corporation
Company Headquarters: Minnesota, US Founded: 1986 Workforce: 215 Company Working: MGC Diagnostics Corporation creates, produces, and markets non-invasive diagnostic tools for the detection, management, and treatment of cardiorespiratory disease. It provides cardiovascular exercise systems, pulmonary function testing equipment, flow sensors, gas analyzers, spirometers, and related consumables. The company's products have applications in figuring out the right nutritional support needs, evaluating the effectiveness of prescription medications, and using diagnostics to look for early indications of cardiac and pulmonary failure. Through a direct sales force and distributors, it offers its products under the MGC diagnostics and Medisoft brand names to hospitals, university-based medical centers, organizations, clinics, doctor's offices, pharmaceutical firms, medical device producers, and clinical research organizations. Additionally, the business works as a division of CAIRE, Inc. (US). Furthermore, the company has operations in the US, Belgium, France, Australia, and Germany.
Halma plc
Company Headquarter: UK Founded: 1894 Workforce: 6,341 employees worldwide Company Working: Halma plc. has a core focus on safety, health, and environment and its products provide innovative solutions for many problems related to health. The company operates in four sectors. Its process safety segment offers safety systems to control hazardous industrial processes and access to dangerous machines, gas detection instruments, pressure management products, key interlocks, and interlocking systems. The infrastructure safety segment offers fire detection systems, smoke detectors, specialist fire suppression systems, people and vehicle flow solutions, security sensors, and elevator safety products. The medical segment offers devices that assess eye health and assist with eye surgery and primary care applications. The environmental and analysis segment offers market-leading optoelectronic technology and sensors.
COSMED Srl
Company Headquarters: Rome, Italy Founded: 1980 Workforce: ~ 200 Company Working: COSMED srl develops, manufactures, and sells diagnostic medical equipment globally. It offers diagnostic equipment for the metabolism, lungs, and body composition. The company's products include spirometers, Pulmonary Function Test (PFT), Cardiopulmonary Exercise Test (CPET), and indirect calorimetry diagnostic equipment. In addition, COSMED products are designed for either professional or medical use in a variety of settings, including hospitals, clinics, primary care, universities, and education in human physiology, clinical nutrition, commercial weight management, human performance centers, sports institutions, and the health club industry. Moreover, the company has a distributor network that spans more than 80 nations. Furthermore, the company has direct operations in the US, Australia, Switzerland, France, Germany, Netherlands, Denmark, Hong Kong, and the UK.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Cardiopulmonary Exercise Testing Market